<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1096155" disease_type="Disease or Syndrome" abbrv="">Macrophage activation syndrome</z:e> (MAS) belongs to secondary <z:e sem="disease" ids="C0024291" disease_type="Disease or Syndrome" abbrv="">hemophagocytic lymphohistiocytosis</z:e> (HLH) syndrome </plain></SENT>
<SENT sid="1" pm="."><plain>It is usually associated with <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We retrospectively reviewed our hospital's medical records of 102 HLH/MAS patients from the past 20 years </plain></SENT>
<SENT sid="3" pm="."><plain>Demographics, clinical data, treatment, and outcomes were analyzed </plain></SENT>
<SENT sid="4" pm="."><plain>Among 102 patients, eight patients with underlying juvenile systemic <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> erythematous (two patients), <z:e sem="disease" ids="C0026272" disease_type="Disease or Syndrome" abbrv="MCTD">mixed connective tissue disease</z:e> (one patient), primary anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> syndrome (one patient), and systemic type <z:hpo ids='HP_0005681'>juvenile rheumatoid arthritis</z:hpo> (sJRA; four patients) with 13 episodes of MAS were studied </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical manifestations of MAS included <z:hpo ids='HP_0001945'>fever</z:hpo> (100 %), <z:hpo ids='HP_0001433'>hepatosplenomegaly</z:hpo> (77 %), <z:hpo ids='HP_0002716'>lymphadenopathy</z:hpo> (38 %), <z:hpo ids='HP_0000988'>skin rash</z:hpo> (62 %), and neurological involvement (31 %) </plain></SENT>
<SENT sid="6" pm="."><plain>Laboratory features included <z:hpo ids='HP_0001882'>leukopenia</z:hpo> (54 %), <z:hpo ids='HP_0001903'>anemia</z:hpo> (46 %), <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (77 %), <z:hpo ids='HP_0000952'>jaundice</z:hpo> (27 %), <z:hpo ids='HP_0011900'>hypofibrinogenemia</z:hpo> (40 %), decreased erythrocyte sedimentation rate (67 %), and <z:hpo ids='HP_0002910'>elevated liver enzymes</z:hpo> (77 %), <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase (100 %), ferritin (88 %), <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (91 %), C-reactive protein (85 %), plasma D-dimer (50 %), and <z:e sem="disease" ids="C0876991" disease_type="Disease or Syndrome" abbrv="">hemophagocytosis</z:e> in bone marrow (83 %) </plain></SENT>
<SENT sid="7" pm="."><plain>The Epstein-Barr virus and <z:e sem="disease" ids="C0001486" disease_type="Disease or Syndrome" abbrv="">adenovirus infection</z:e> triggered MAS in two patients with sJRA </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="6888">Methylprednisolone</z:chebi> pulse therapy was effective in two out of three patients, and high-dose intravenous immunoglobulin (IVIG) was effective in two out of six patients </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with sJRA responded well to <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Complications included <z:e sem="disease" ids="C0029118" disease_type="Disease or Syndrome" abbrv="">opportunistic infection</z:e> with Pneumocystis jiroveci, multiple organ failure, and intensive care unit <z:hpo ids='HP_0003198'>myopathy</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>The mortality rate was one out of eight (12.5 %) </plain></SENT>
<SENT sid="12" pm="."><plain>Our results showed that MAS could be fatal and complicate various pediatric <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>It generally has a good response to <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and IVIG </plain></SENT>
<SENT sid="14" pm="."><plain>Prompt recognition and timely treatment can result in good outcomes </plain></SENT>
</text></document>